title: PCR for monitoring of minimal residual disease in hematologic malignancy.
abstract: Monitoring minimal residual disease (MRD) is useful to evaluate therapeutic response and risk of relapse in patients with hematologic malignancy. Currently available quantitative MRD assays are fluorescence in situ hybridization of chromosomal aberrations; multiparameter flow cytometry of leukemia-associated immunophenotypes; and quantitative polymerase chain reaction (qPCR) analysis of fusion genes, immunoglobulin/T-cell receptor gene rearrangements, genetic alterations, or over-expressed genes. Among the PCR-based markers, genetic alterations are found in acute myelogenous leukemia patients with cytogenetically normal karyotype and can be considered as applicable targets for monitoring of MRD. Screening, confirmation and quantification procedures are important to develop the patient- or tumor-specific MRD assays using the PCR-based markers. Wild-type blocking PCR or coamplification at lower denaturing temperature-PCR is suited for screening of low-abundant genetic alterations, and allele-specific qPCR using primers including mismatched base and locked nucleic acids can quantify not only insertion and duplication of several nucleotides but also single nucleotide mutation in the presence of an excess amount of wild-type nucleotides. In addition to the well-established MRD markers, such as immunoglobulin/T-cell receptor gene rearrangements and fusion genes, utilizing potential MRD markers such as genetic alterations may expand the spectrum of patients in whom MRD can be monitored.
authors: Department of Laboratory Medicine, Shinshu University Hospital, Asahi, Matsumoto, Japan. kmatsuda@shinshu-u.ac.jp
authors: Kazuyuki
authors: K
authors: Matsuda
authors: Mitsutoshi
authors: M
authors: Sugano
authors: Takayuki
authors: T
authors: Honda
mesh_terms: D050939:Gene Fusion; D005819:Genetic Markers; D019337:Hematologic Neoplasms / Q000235:genetics / Q000503:physiopathology*; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D009154:Mutation; D018365:Neoplasm, Residual / Q000235:genetics / Q000503:physiopathology*; D016133:Polymerase Chain Reaction / Q000379:methods*; D020641:Polymorphism, Single Nucleotide; D012333:RNA, Messenger / Q000235:genetics; D011948:Receptors, Antigen, T-Cell / Q000235:genetics
chemical_list: D005819:Genetic Markers; D012333:RNA, Messenger; D011948:Receptors, Antigen, T-Cell